Incretin Mimetics Global Market Report 2026

The incretin mimetics market size has grown strongly in recent years. It will grow from $21.01 billion in 2025 to $22.61 billion in 2026 at a compound annual growth rate (CAGR) of 7.6%. The growth in the historic period can be attributed to increasing prevalence of type 2 diabetes, rising global obesity rates, advancement in glp-1 receptor agonist development, growing awareness of metabolic syndrome management, expansion of reimbursement coverage for diabetes therapies.

The incretin mimetics market size is expected to see strong growth in the next few years. It will grow to $30.57 billion in 2030 at a compound annual growth rate (CAGR) of 7.8%. The growth in the forecast period can be attributed to increasing demand for dual and triple agonist therapies, growing adoption of weight management pharmacotherapy, rising cardiovascular risk reduction focus in diabetes care, expansion of biologic drug manufacturing capacity, increasing patient preference for convenient dosing regimens. Major trends in the forecast period include increasing adoption of once-weekly glp-1 injectable therapies, rising demand for oral glp-1 formulations, growing expansion of incretin mimetics in obesity management, integration of cardiovascular outcome benefits in treatment protocols, rising combination therapy approaches for metabolic disorders.

The increasing prevalence of Type 2 diabetes is expected to propel the growth of the incretin mimetics market in the coming years. Type 2 diabetes is a chronic disorder in which the body becomes resistant to insulin or produces insufficient insulin, leading to elevated blood glucose levels. The rising prevalence of Type 2 diabetes is primarily driven by increasing obesity rates, as excess body weight significantly enhances insulin resistance and the risk of disease onset. Incretin mimetics play a crucial role in managing Type 2 diabetes, particularly among overweight and obese patients, by improving glucose-dependent insulin secretion, suppressing glucagon release, and promoting weight loss. For instance, in 2023, according to Diabetes Australia, an Australia-based non-for-profit organization, approximately 1.5 million Australians (5.6% of the population) were living with diagnosed diabetes, with Type 2 diabetes accounting for 86.7% of cases. Therefore, the increasing prevalence of Type 2 diabetes is driving the growth of the incretin mimetics market.

Leading companies operating in the incretin mimetics market are increasingly focused on developing biosimilar and next-generation therapeutic solutions to enhance glycemic control and improve outcomes for patients with Type 2 diabetes. Next-generation therapeutic solutions refer to advanced or innovative treatments designed to improve efficacy, safety, affordability, or patient adherence compared with conventional therapies. For example, in January 2024, Glenmark Pharmaceuticals Limited, an India-based pharmaceutical company, launched a biosimilar version of the widely used anti-diabetic drug liraglutide in India. This biosimilar GLP-1 receptor agonist aims to provide a more accessible and cost-effective treatment option, thereby expanding patient access and supporting improved treatment adherence. The biosimilar is designed to deliver comparable efficacy, safety, and quality to the reference product. Such developments support reliable glycemic control across diverse patient populations and contribute to reducing disease-related complications, thereby improving the overall management of Type 2 diabetes.

In May 2025, Septerna, Inc., a US-based clinical-stage biotechnology company developing a range of oral small-molecule medicines targeting G protein-coupled receptors (GPCRs), entered into a collaboration with Novo Nordisk. Under this partnership, Septerna and Novo Nordisk intend to develop and commercialize new incretin mimetic therapies for metabolic diseases, combining Septerna’s GPCR-focused innovation with Novo Nordisk’s extensive global capabilities in development, manufacturing, and commercialization. Novo Nordisk is a Denmark-based provider of incretin mimetics, including GLP-1 receptor agonists, and markets several blockbuster therapies for treating Type 2 diabetes and obesity.

Major companies operating in the incretin mimetics market are Roche Holding AG, Merck Co Inc, Pfizer Inc., Sanofi S.A., AstraZeneca PLC, Eli Lilly Company, Novo Nordisk A/S, Takeda Pharmaceutical Company Limited, Amgen Inc., Boehringer Ingelheim International GmbH, Sun Pharmaceutical Industries Limited, Dr Reddys Laboratories Limited, Cipla Limited, Hikma Pharmaceuticals PLC, Lupin Limited, Biocon Limited, Torrent Pharmaceuticals Limited, Hanmi Pharmaceutical Co Ltd, Innovent Biologics Inc., Zealand Pharma A/S, Gan Lee Pharmaceuticals Co Ltd, Jiangsu Hansoh Pharmaceutical Group Company Limited.

North America was the largest region in the incretin mimetics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the incretin mimetics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the incretin mimetics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The incretin mimetics market consists of sales of lixisenatide injection pens, tirzepatide injection pens, albiglutide injection pens, and oral semaglutide tablets. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Incretin mimetics are medications that mimic the effects of natural incretin hormones, mainly glucagon-like peptide-1 (GLP-1), to regulate blood glucose levels. They stimulate glucose-dependent insulin release, inhibit glucagon secretion, slow gastric emptying, and increase satiety. These drugs are widely used for managing type 2 diabetes and are increasingly applied in obesity treatment due to their metabolic benefits.

The key drug types of incretin mimetics include GLP-1 agonists and DPP-4 inhibitors. GLP-1 agonists regulate blood glucose levels by enhancing insulin secretion and inhibiting glucagon release. They are administered via injectable and oral formulations and distributed through hospital pharmacies, retail pharmacies, and online pharmacies. Applications include type 2 diabetes, obesity, and cardiovascular diseases, serving hospitals, specialty clinics (diabetology and endocrinology), and homecare settings.

Tariffs on imported active pharmaceutical ingredients, biologic raw materials, and injectable device components are impacting the incretin mimetics market by increasing manufacturing and distribution costs, particularly affecting GLP-1 agonists and advanced oral formulations. Regions dependent on cross-border pharmaceutical supply chains, including North America, Europe, and Asia-Pacific, are most affected, especially hospital and retail pharmacy channels. Higher costs may influence drug pricing and reimbursement dynamics. However, tariffs are also encouraging localized API production, domestic biologics manufacturing expansion, and investment in regional supply chain resilience, supporting long-term market stability.

The incretin mimetics market research report is one of a series of new reports that provides incretin mimetics market statistics, including incretin mimetics industry global market size, regional shares, competitors with a incretin mimetics market share, detailed incretin mimetics market segments, market trends and opportunities, and any further data you may need to thrive in the incretin mimetics industry. This incretin mimetics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

This product will be delivered within 1-3 business days.